Table 3.
Primary liver cancer age-standardised net-survival by nation, sex, subtype, and 5-year cohort.
| Cohort | UK |
England |
Scotland |
Wales |
Northern Ireland |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Net survival | 95% CI | N | Net survival | 95% CI | N | Net survival | 95% CI | N | Net survival | 95% CI | N | Net survival | 95% CI | |
|
1-year survival | |||||||||||||||
| PLC | |||||||||||||||
| 1997–2001 | 11,036 | 21.7 | (20.9–22.5) | 9,001 | 21.4 | (20.5–22.3) | 1,177 | 25.4 | (22.8–28.0) | 632 | 20.7 | (17.5–24) | 226 | 18.6 | (13.8–24.1) |
| 2013–2017∗ | 29,029 | 40.6 | (40.0–41.2) | 23,773 | 40.2 | (39.6–40.9) | 3,107 | 44.6 | (42.8–46.4) | 1,487 | 37.7 | (35.2–40.3) | 656 | 39.9 | (36.0–43.7) |
| Total change | 18.9 | 18.8 | 19.2 | 17.0 | 21.3 | ||||||||||
| HCC | |||||||||||||||
| 1997–2001 | 4,757 | 23.7 | (22.5–24.9) | 3,865 | 23.6 | (22.3–25.0) | 564 | 27.3 | (23.6–31.1) | 239 | 17.8 | (13.2–23) | 89 | 21.1 | (13.2–30.3) |
| 2013–2017∗ | 16,091 | 46.7 | (45.9–47.5) | 12,781 | 46.2 | (45.3–47.1) | 2,052 | 52.4 | (50.1–54.6) | 808 | 42.0 | (38.5–45.5) | 432 | 45.4 | (40.5–50.1) |
| Total change | 23.0 | 22.6 | 25.1 | 24.2 | 24.3 | ||||||||||
| ICCA | |||||||||||||||
| 1997–2001 | 4,573 | 22.6 | (21.4–23.9) | 3,711 | 22.2 | (20.9–23.6) | 488 | 25.3 | (21.4–29.4) | 264 | 26.6 | (21.3–32.2) | 110 | 14.6 | (8.7–22.1) |
| 2013–2017∗ | 9,795 | 30.5 | (29.6–31.4) | 8,109 | 30.7 | (29.7–31.7) | 958 | 28.5 | (25.6–31.5) | 568 | 30.9 | (27.1–34.9) | 173 | 28.3 | (21.6–35.3) |
| Total change | 7.9 | 8.5 | 3.2 | 4.3 | 13.7 | ||||||||||
| Other | |||||||||||||||
| 1997–2001 | 1,648 | 13.2 | (11.6–14.9) | 1,397 | 12.9 | (11.2–14.8) | 108 | 15.5 | (9.3–23.2) | 117 | 15.9 | (9.8–23.2) | 26 | 13.2 | (3.6–29.2) |
| 2013–2017∗ | 3,065 | 37.9 | (36.1–39.6) | 2,831 | 38.2 | (36.3–40.0) | Insuff | 102 | 41.3 | (31.4–51.1) | 50 | 27.5 | (15.8–40.7) | ||
| Total change |
24.7 |
25.3 |
NC |
25.4 |
14.3 |
||||||||||
|
2-year survival | |||||||||||||||
| PLC | |||||||||||||||
| 1997–2001 | 2,300 | 12.8 | (12.1–13.4) | 1,848 | 12.7 | (12–13.4) | 286 | 13.6 | (11.6–15.8) | 126 | 13.7 | (11.1–16.6) | 41 | 7.0 | (4.1–11.1) |
| 2012–2016∗ | 10,753 | 27.2 | (26.6–27.7) | 8,686 | 26.7 | (26.1–27.3) | 1,286 | 31.4 | (29.7–33.2) | 530 | 25.3 | (23.0–27.7) | 241 | 26.1 | (22.6–29.7) |
| Total change | 14.4 | 14.0 | 17.8 | 11.6 | 19.1 | ||||||||||
| HCC | |||||||||||||||
| 1997–2001 | 1,085 | 15.4 | (14.3–16.5) | 879 | 15.5 | (14.3–16.7) | 148 | 15.6 | (12.6–18.9) | 41 | 12.2 | (8.3–16.9) | 18 | 11.6 | (5.7–19.8) |
| 2012–2016∗ | 6,783 | 33.8 | (33.0–34.6) | 5,277 | 33.1 | (32.2–34.0) | 1,002 | 39.7 | (37.4–42.0) | 326 | 32.1 | (28.7–35.5) | 185 | 31.4 | (26.8–36) |
| Total change | 18.4 | 17.6 | 24.1 | 19.9 | 19.8 | ||||||||||
| ICCA | |||||||||||||||
| 1997–2001 | 993 | 11.0 | (10.1–12.0) | 791 | 10.7 | (9.7–11.8) | 118 | 11.9 | (9.1–15.1) | 67 | 18.7 | (14.0–23.8) | 15 | 2.4 | (0.6–7.0) |
| 2012–2016∗ | 2,739 | 15.8 | (15.0–16.6) | 2,273 | 16.1 | (15.3–17) | 255 | 13.4 | (11.2–15.8) | 157 | 14.1 | (11.3–17.3) | 42 | 14.6 | (9.4–20.8) |
| Total change | 4.8 | 5.4 | 1.5 | -4.6 | 12.2 | ||||||||||
| Other | |||||||||||||||
| 1997–2001 | 208 | 8.5 | (7.1–9.9) | 172 | 8.7 | (7.2–10.3) | 16 | 7.0 | (3.1–13.1) | 2 year>1 year | <10 | ||||
| 2012–2016∗ | 1,139 | 24.4 | (22.9–26) | 1,066 | 24.5 | (22.9–26.2) | 14 | 12.7 | (6.1–21.9) | 40 | 32.6 | (23.1–42.5) | 18 | 10.0 | (3.3–21.4) |
| Total change |
15.9 |
15.8 |
5.7 |
NC |
NC |
||||||||||
|
5-year survival | |||||||||||||||
| PLC | |||||||||||||||
| 1997–2001 | 1,300 | 7.2 | (6.7–7.8) | 1,053 | 7 | (6.4–7.6) | 146 | 8.5 | (6.8–10.5) | 81 | 9.1 | (6.8–11.8) | 14 | 3.8 | (1.6–7.5) |
| 2009–2013∗ | 5,018 | 14.3 | (13.8–14.8) | 3,975 | 13.9 | (13.3–14.4) | 647 | 18.4 | (16.6–20.2) | 253 | 14.0 | (11.9–16.3) | 123 | 14.2 | (11.0–17.9) |
| Total change | 7.1 | 6.9 | 9.9 | 4.9 | 10.4 | ||||||||||
| HCC | |||||||||||||||
| 1997–2001 | 675 | 9.4 | (8.5–10.4) | 552 | 9.3 | (8.2–10.3) | 80 | 10.8 | (8.1–14.1) | 27 | 8.7 | (5.3–13.2) | <10 | ||
| 2009–2013∗ | 3,172 | 18.3 | (17.5–19.1) | 2,386 | 17.6 | (16.7–18.5) | 514 | 23.9 | (21.5–26.4) | 169 | 17.2 | (14.0–20.7) | 88 | 16.5 | (12.2–21.4) |
| Total change | 8.9 | 8.3 | 13.1 | 8.5 | NC | ||||||||||
| ICCA | |||||||||||||||
| 1997–2001 | 464 | 4.4 | (3.8–5.1) | 367 | 4.2 | (3.5–5.0) | 53 | 4.6 | (2.8–7.2) | 46 | 9.8 | (6.3–14.2) | <10 | ||
| 2009–2013∗ | 1,088 | 6.1 | (5.6–6.7) | 890 | 6.0 | (5.4–6.7) | 108 | 5.2 | (3.6–7.2) | 61 | 8.0 | (5.6–10.9) | 21 | 7.8 | (3.6–14.2) |
| Total change | 1.7 | 1.8 | 0.6 | -1.8 | NC | ||||||||||
| Other | |||||||||||||||
| 1997–2001 | 128 | 5.6 | (4.5–7.0) | 111 | 5.3 | (4.2–6.8) | <10 | 10 | 9.7 | (4.6–17.3) | SE>0.2 | ||||
| 2009–2013∗ | 651 | 17.3 | (15.8–19.0) | 607 | 17.7 | (16.0–19.4) | <10 | 19 | 23.3 | (13.2–35.4) | 13 | 19.2 | (10.0–31.0) | ||
| Total change | 11.7 | 12.4 | NC | 13.6 | NC | ||||||||||
∗1 year earlier for Wales (i.e. 2012–2016 for 1-year survival, 2011–2015 for 2-year, and 2008–2012 for 5-year). Suppressed results: Insuff, no deaths or data in at least 1 age band; <10, less than 10 cases in total; SE >0.2, standard error greater than 0.2; 2 year>1 year, 2-year survival longer than 1-year survival. HCC, hepatocellular carcinoma; ICCA, intrahepatic cholangiocarcinoma; NC, not calculatable; PLC, primary liver cancer.